Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

• Status: Enrolling by invitation
• Trial end date: 2026-08-01

Summary

This study is phase II, open label, clinical trial to determine the efficacy of Olaparib maintenance with Bevacizumab and Pembrolizumab by assessment progression-free survival(6 months PFS rate) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Yonsei University
• Treatments: Bevacizumab; Olaparib; Pembrolizumab